Citations

Clear

6273 citation(s) found for "To, Andrew".

Enhancing team development in an internal medicine resident continuity clinic
Wingo, Majken T. , Leasure, Emily L. , Wallace, Jocelyn A., Huber, Jill M. , Mathias, Tammy R., Thomas, Kris G., Halvorsen, Andrew J.

Mayo Clinic

Medical Education Online | November 20, 2024 | Volume: 29 | Issue: 1 | Pages: No page available

10.1080/10872981.2024.2430570 | PMID 39563076 Get It

Neuro-Ophthalmic Literature Review
Chen, John J. , Hung, Wei-Che , Jindahra, Panitha , Vaphiades, Michael S., Zhang, Xiaojun , Chen, John J , Mak, Andrew C. Y. , McClelland, Collin M. , Verma, Rashmi , Xie, Jim Shenchu

Mayo Clinic

Neuro-Ophthalmology | November 19, 2024 | Volume: 48 | Issue: 6 | Pages: 464-471

10.1080/01658107.2024.2408954 Get It

Pharmacist Medication Titration Program for Patients With Cardiac Sarcoidosis and Systolic Heart Failure: A Retrospective Cohort Study
Sykora, Daniel , Olson, Nicole, Kim, B Michelle , Bratcher, Melanie, Elwazir, Mohamed Y. , Young, Kathleen A. , Ryan, Sami, Brodin, Michelle, Anderson, Jan, Saunders, Jeremiah, Ezzeddine, Omar Abou, Bois, John P. , Giudicessi, John R. , Rosenbaum, Andrew , AbouEzzeddine, Omar F. , Churchill, Robert , Elwazir, Mohamed , Young, Kathleen , Abou Ezzeddine, Omar, Giudicessi, J R , Cooper, Leslie T , Rosenbaum, Andrew N , AbouEzzeddine, Omar F , Kim, B Michelle , Cooper, Leslie T.

Mayo Clinic

Journal of the American Heart Association | November 18, 2024 | Volume: 13 | Issue: 24 | Pages: No page available

10.1161/jaha.124.038965 | PMID 39556701 Get It

Background A multidisciplinary approach improves guideline‐directed medical therapy in systolic heart failure (HF), but its efficacy in patients with HF due to cardiac sarcoidosis is unreported. Methods and Results In a retrospective cohort study, we reviewed 848 patients from our institutional cardiac sarcoidosis clinics, identifying those with a cardiac sarcoidosis diagnosis, HF (left ventricular ejection fraction <50%) at index evaluation, and echocardiograms within 90 days and 11 to 36 months. Patients were stratified by participation in a pharmacist‐led medication therapy management (MTM) program for guideline‐directed medical therapy optimization (MTM versus non‐MTM [NMTM]) without randomization. Demographics, left ventricular ejection fraction, guideline‐directed medical therapy (quantified by Kansas City Medical Optimization score), and immunosuppressive therapy were assessed. Primary outcomes included changes in Kansas City Medical Optimization score, left ventricular ejection fraction, and cardiovascular event–free survival (unplanned HF hospitalization, left ventricular assist device /heart transplant, or death). The final cohort included 111 patients (median age, 57 years; 34% women; 64% New York Heart Association class I–II); 43 (39%) were MTM and 68 (61%) were NMTM. Mean Kansas City Medical Optimization score was similar at index evaluation (MTM, 23.2; NMTM, 29.6; P =0.83). At follow‐up (median, 16 months), the Kansas City Medical Optimization score increased significantly in both groups (MTM, 23.2 to 74.8; P <0.001; NMTM, 29.6 to 58.7; P <0.001) but was higher in MTM ( P =0.001). Mean left ventricular ejection fraction trended toward higher values in MTM (44.4% versus 40.0%, P =0.05). The primary clinical outcome occurred in 1 MTM (2.3%) and 16 NMTM (23.5%) patients, with higher risk in NMTM (hazard ratio, 11.97 [95% CI, 1.58–90.54]; P =0.002). Conclusions In this retrospective cohort study, a pharmacist‐led MTM program was associated with favorable guideline‐directed medical therapy optimization and lower risk of adverse cardiovascular outcomes in patients with cardiac sarcoidosis with HF.
Phenotypic and oncological insights in ANNA1 autoimmunity: Age stratification and biomarker analysis
Paramasivan, Naveen Kumar , Karsten, Carley , Zahid, Anza , Kherbek, Haidara , Ζεκερίδου, Αναστασία , Sista, Sri Raghav, Dasari, Surendra , Mangioris, Georgios , Mills, John R. , Pittock, Sean J, Dubey, Divyanshu , Pittock, Sean J. , Dubey, Divyanshu , Pittock, S J , Masoud, Majed, Kherbek, Haidara , Zekeridou, Anastasia , Knight, Andrew M, McKeon, Andrew , Dubey, Divyanshu , Dubey, Divyanshu , Paramasivan, Naveen K , Masoud, Majed, Knight, Andrew M., McKeon, Andrew

Mayo Clinic

Annals of Clinical and Translational Neurology | November 18, 2024 | Volume: 12 | Issue: 2 | Pages: 280-290

10.1002/acn3.52254 | PMID 39556523 Get It

AbstractObjectiveTo describe the phenotypes, oncological associations, biomarker profiles, and outcomes across different age groups in patients with ANNA1 (anti‐Hu) autoimmunity.MethodsA retrospective review of patients with ANNA1‐IgG in serum/CSF between January 1, 2001, and December 31,2019 was performed. Patients were classified into three groups based on the age of symptom onset. Phage immunoprecipitation sequencing (PhIP‐Seq) and neurofilament light chain (NfL) measurements were done in patient sera/CSF with archived samples.ResultsOf 122 patients, 81 (66%), 20 (16%), and 21 (17%) patients belonged to older adults, young adults, and pediatric groups, respectively. Lung cancer and neuromuscular presentations were more common in older adults (p < 0.001), while limbic encephalitis and neuroblastoma were more common in pediatric patients (p < 0.005). Most young adults (75%) did not have cancer identified. Proportions of patients with a favorable response to immunotherapy were 20%, 30%, and 52% among older adults, young adults, and pediatric groups, respectively. PhIP‐Seq demonstrated significant enrichment for ELAVL4 peptides especially for amino acids 240–289, in the majority of samples evaluated (36/67, 54%). ZIC and SOX2 peptides were significantly enriched in those with central nervous system presentations. Serum NfL levels were elevated in patients with cancer and those with poor long‐term outcomes.InterpretationYoung adults with ANNA1 autoimmunity phenotypically resembled older adults but rarely had an underlying cancer. Pediatric patients frequently presented with limbic encephalitis and neuroblastoma and often responded favorably to immunotherapy. Distinct antigenic signatures may underlie differences in clinical presentations. Serum NfL levels may be a biomarker of poor long‐term outcomes in ANNA1 autoimmunity.
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM
Desai, Milind Y. , Wolski, Kathy , Owens, Anjali , Geske, Jeffrey B. , Saberi, Sara , Wang, Andrew , Cremer, Paul , Lakdawala, Neal K. , Tower‐Rader, Albree, Naidu, Srihari S. , Smedira, Nicholas G. , Gong, Zhiqun, Mudarris, Lana, Lampl, Kathy, Sehnert, Amy J. , Nissen, Steven E. , Investigators, for the VALOR-HCM, Sherrid, Mark , Cremer, Paul C , Lakdawala, Neal K , Tower-Rader, Albree , Naidu, Srihari S , Smedira, Nicholas G , Schaff, Hartzell , Sehnert, Amy J , Nissen, Steven E , Geske, Jeffrey B , Saberi, Sara , Wang, Andrew , Sherrid, Mark V. , Fermin, David , Schaff, Hartzell V. , Investigators, for the VALOR-HCM

Mayo Clinic

Circulation | November 18, 2024 | Volume: 151 | Issue: 19 | Pages: 1378-1390

10.1161/circulationaha.124.072445 | PMID 39556124 Get It

BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov ; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report examined the longer-term effect of mavacamten through end of treatment at week 128. METHODS: A double-blind randomized placebo-controlled multicenter trial at 19 sites in the United States included symptomatic obstructive HCM patients referred for SRT (enrollment July 2020 through October 2021). The group initially randomized to mavacamten continued the drug for 128 weeks and the placebo to mavacamten group from week 16 to 128 (112-week exposure). Dose titrations were performed using echocardiographic left ventricular outflow tract gradient and left ventricular ejection fraction measurements. The principal end point was proportion of patients proceeding with SRT or remaining guideline-eligible at week 128. RESULTS: At week 128, 17 of 108 (15.7%) patients in the total study sample met the composite end point (7 underwent SRT, 1 was SRT-eligible, and 9 SRT-status unevaluable). Additionally, 87 of 108 (80.5%) patients demonstrated ≥1 New York Heart Association class improvement by week 128, and 52 of 108 (48.1%) demonstrated ≥2, with a sustained reduction in resting and Valsalva left ventricular outflow tract gradients of 38.2 mm Hg and 59.4 mm Hg, respectively. Ninety-five of 108 (88%) patients transitioned to commercial mavacamten. Overall, 15 of 108 (13.8%) patients (5.41 per 100 patient-years) had an left ventricular ejection fraction <50% (2 with left ventricular ejection fraction ≤30%; 1 death). Of these, 12 of 15 (80%) continued treatment. New-onset atrial fibrillation occurred in 11 (10.2%) patients (4.55 per 100 patient-years). CONCLUSIONS: In severely symptomatic obstructive HCM patients, sustained freedom from SRT was observed at 128 weeks, with nearly 90% patients remaining on long-term mavacamten. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04349072.
Novel HMGA2::COL14A1 Fusion Identified in Xanthogranulomatous Epithelial Tumor/Keratin‐Positive Giant Cell Tumor
Dehner, Carina , Buehler, Darya, Hofich, Christopher, Halling, Kevin C. , Folpe, Andrew L. , Dehner, Carina A

Mayo Clinic

Genes, Chromosomes and Cancer | November 18, 2024 | Volume: 63 | Issue: 11 | Pages: No page available

10.1002/gcc.70010 | PMID 39552601 Get It

ABSTRACTXanthogranulomatous epithelial tumor (XGET)/Keratin‐positive giant cell tumor (KP‐GCT) represents a spectrum of recently described neoplasms characterized by a proliferation of distinctive mononuclear cells expressing keratin within a background of osteoclast‐like giant cells, mixed inflammatory cells, and a variably prominent xanthogranulomatous component. Recent studies demonstrated a recurrent HMGA2::NCOR2 fusion in many cases. We herein describe a case of XGET/KP‐GCT arising in the right femoral head of a 19‐year‐old male harboring a rare novel HMGA2::COL14A1 fusion.
Is minimally invasive glaucoma surgery killing trabeculectomies?
Loon, Seng Chee, White, Andrew , Ang, Bryan C H

Mayo Clinic

Current Opinion in Ophthalmology | November 15, 2024 | Volume: 36 | Issue: 2 | Pages: 146-151

10.1097/icu.0000000000001108 | PMID 39774269 Get It

Purpose of review The introduction of minimally invasive glaucoma surgery (MIGS) has changed the surgical landscape of glaucoma surgery. For more than four decades, the most commonly performed glaucoma surgery around the world has been the trabeculectomy. This article examines whether trabeculectomy is still the predominant procedure in glaucoma today, in the context of rapidly emerging MIGS devices and procedures. Recent findings There is a growing trend of mild to moderate glaucoma cases undergoing MIGS procedures instead of trabeculectomy. Glaucoma drainage device implantation may also have taken away a significant share of the filtering surgery performed for more severe glaucoma. In addition, the availability and economics of implants has an influence on the prevalence of trabeculectomy. Summary Currently, trabeculectomy surgery is still the most common glaucoma surgery performed around the world. However, the proportion of glaucoma surgeries undergoing MIGS is increasing rapidly.
Abstract 4147597: Venoarterial Extracorporeal Membrane Oxygenation With and Without Left Ventricular Unloading in Patients With Cardiac Arrest
Wardhere, Abdirahman , Mohamoud, Abdilahi , abdallah, nadhem, Ismayl, Mahmoud , Goldsweig, Andrew M.

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4147597 Get It

Background: Extracorporeal cardiopulmonary resuscitation (ECPR) using venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a promising strategy for refractory cardiac arrest. However, the role of left ventricular (LV) unloading during ECPR remains uncertain. Methods: We queried the United States National Inpatient Sample (2016-2021) to identify adult patients with out-of-hospital (OHCA) and in-hospital cardiac arrest (IHCA) who received ECPR. Patients were stratified based on the use of either VA-ECMO only or VA-ECMO with intra-aortic balloon pump (IABP) or VA-ECMO with Impella (ECPELLA) for ventricular unloading. Multivariable logistic regression was used to compare in-hospital outcomes between the groups. Results: Among 6,915 patients receiving ECPR, VA-ECMO alone was used in 5,145 (74.4%), VA-ECMO-IABP in 809 (11.7%), and ECPELLA in 961 (13.9%). The LV unloading groups more frequently presented with ventricular tachycardia/fibrillation (61.1% and 72.4% vs. 43.9%, both p<0.01), while the VA-ECMO only group more often presented with pulseless electrical activity/asystole (56.1% vs. 38.9% and 27.6%, both p<0.01). In IHCA patients, ECPELLA was associated with 50% lower odds of in-hospital mortality compared to VA-ECMO alone (adjusted odds ratio [aOR] 0.50, 95% CI 0.31-0.81, p<0.01). No significant difference was found in OHCA patients. VA-ECMO-IABP was not associated with a mortality benefit vs. VA-ECMO alone in either OHCA or IHCA (Figure 1). Cardiovascular complications were significantly higher in both LV unloading groups compared to the VA-ECMO only group in OHCA subgroup (90% and 95% vs. 73.3%, both p<0.01) while IHCA subgroup only showed higher significant rates in ECPELLA compared to VA-ECMO alone (89.3% vs. 81%, p=0.04) (Figure 2). After adjustment for potential confounders, VA-ECMO-IABP (aOR 2.79, 95% CI 1.02-7.60, p=0.04) and ECPELLA (aOR 6.92, 95% CI 2.09-22.94, p<0.01) were associated with significantly higher odds of cardiovascular complications compared to VA-ECMO alone among OHCA patients, but not among IHCA patient. There were no statistically significant differences in neurologic, renal, and hematologic complications between the three groups in either OHCA or IHCA patients (Figure 3). Conclusion: In this nationwide study, LV unloading with ECPELLA was associated with improved survival in IHCA patients but not in OHCA patients compared to VA-ECMO alone. The addition of IABP to VA-ECMO was not associated with a mortality benefit.
Abstract 4147545: Adverse Events with Pulsed Field Ablation - A Review of the Food and Drug Administration’s Manufacturer and User Facility Device Experience Database
Cooper, Julie , Zagrodzky, William , Zagrodzky, Jason , Omotoye, Samuel, Kaplan, Andrew , Bunch, T. Jared , Daniels, James , Sardana, Mayank , Link, Mark S.

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4147545 Get It

Introduction: Pulsed field ablation (PFA) is an adaptation of direct current ablation first used for catheter ablation in the 1980s. Expectations of a reduced risk profile led to the current resurgence in investment and interest in the technology as a potential alternative energy source for ablations to treat atrial fibrillation (AF). However, reports of adverse events, including new risks, are increasing. Research Question: How many adverse effects are reported with the use of newly available PFA systems? Aims: Quantify and describe the adverse events from PFA reported to date in the Food and Drug Administration’s (FDA) Manufacturer and User Facility Device Experience (MAUDE) database. Methods: We searched the U.S. FDA’s MAUDE database for all reports filed with the code “QZI”, which is the product code for PFA systems created with the first FDA approvals in February 2024. All reports from inception through April 2024 (a total of 3 months) were included in this review. Per manufacturer presentation in May 2024, approximately 1000 cases utilizing PFA had been captured in a post-market registry of the predominant commercially used technology, but the exact number of cases can not be determined from MAUDE data. Results: A total of 217 adverse events were reported over the first 3 months of US approval, with 91 of these considered patient injuries. These injuries included 10 cases of cardiac tamponade, 7 reports of postoperative arrhythmia, 6 instances of device-related tissue entrapment, 5 cases of hemolysis with impaired renal function, 5 cases of stroke or TIA, including both embolic and hemorrhagic, 3 cases of intraoperative heart block, 2 coronary spasms, and 2 cases of intraoperative ST elevation. (Figure) Of the 91 reported patient safety events, 46 required hospitalization, 13 cases required temporary pacing, 11 required pericardiocentesis, 4 required dialysis, 4 required cardiothoracic surgery, and 2 required cardioversion. Conclusions: A number of adverse events have been reported to the MAUDE database in the first 3 months of FDA approval of PFA. The cardiac electrophysiology community should remain vigilant to ensure that the benefit-risk profile remains acceptable for patient safety.
Abstract 4147050: Genetic Insights into Arrhythmogenic Mitral Valve Prolapse – A Case-Control Study from UK Biobank and NIH All of Us
Dabbagh, Ghaith Sharaf , Hesse, Kerrick , Agnihotri, Ruchi, Kaur, Gurpreet , Gurumoorthi, Manasa, Mitchell, Saige M. , Pargament, Robert, Malik, Adnan , Schuler, Brian, Obeng‐Gyimah, Edmond, Ricci, Fabrizio , Landstrom, Andrew P. , Landstrom, Andrew P , Agnihotri, Ruchi, Shah, Ravi V. , Asatryan, Babken , Galanti, Kristian , Wolfe, Rachel, Malik, Adnan, Munroe, Patricia B. , Somers, Virend K. , Ricci, Fabrizio , Khanji, Mohammed Y , Chahal, C. Anwar A.

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4147050 Get It

Background: Mitral valve prolapse (MVP) is a common valvular abnormality. Observational studies demonstrate an association between MVP and increased risk of sudden cardiac death from ventricular arrhythmias, coined arrhythmogenic MVP. A genetic component has been postulated but remains under-investigated. Hypothesis: Predicted deleterious variants in Mendelian cardiomyopathy and arrhythmia genes are more frequent in arrhythmogenic MVP (aMVP) compared to non-arrhythmogenic MVP. Aims: To comprehensively phenotype and genotype a single-center aMVP cohort and compare to non-aMVP from two large population-based cohorts and investigate their clinical outcomes. Methods: The aMVP cohort included 46 prospectively enrolled patients from a regional referral center for inherited cardiovascular disease and had undergone multi-modality imaging and clinical gene panel testing. The non-aMVP comparator cohorts included 453 participants from the UK Biobank (UKBB), a prospective cohort of 500,000 UK residents, and 1,418 participants from the National Institutes of Health (NIH) All of Us (AoU), a prospective cohort of 450,000 USA participants. Gene variants were annotated in ANNOVAR. Participants with and without pathogenic/likely pathogenic (P/LP) variants reported on ClinVar with ≥2-star level of evidence were considered genotype positive (G+) and negative (G-) respectively. Results: The demographics for aMVP (age 61.2 ± 12.8 years, 56.5% female) and non-aMVP (UKBB: age 59.8 ± 7.3 years, 50.7% female and AoU: age 65.3 ± 13.4 years, 76.2% female) were comparable. G+ participants were more prevalent in the aMVP cohort 10/46 (21.7%) versus non-aMVP in the UKBB 8/453 (1.8%) and in the AoU 21/1418 (1.5%); p<0.001. The most frequently implicated gene in aMVP was TTN . Of 46 in aMVP cohort, 33 (71%) underwent CMR. G+ participants had a higher frequency of late gadolinium enhancement [6/6 (100%) vs. 14/27 (51.8%), p<0.001] and wall motion abnormalities [3/6 (50%) vs. 1/27 (3.7%), p<0.001] compared to G- participants. The aMVP cohort had significantly more implantable cardioverter defibrillator (ICD) implants compared to non-aMVP cohort [5/46 (10.9%) vs. 1/453 in UKBB (0.2%), p<0.001]. G+ aMVP cohort showed a trend for developing heart failure and ICD implants compared to G- aMVP . Conclusion: P/LP variants in cardiomyopathy and arrhythmia genes are more prevalent in aMVP participants compared to non-aMVP participants. This could be a hitherto unrecognized effect modifier predicting aMVP .